Abstract 108P
Background
The efficacy of transarterial chemoembolization (TACE) in Barcelona Clinic Liver Cancer stage B (BCLC-B stage) hepatocellular carcinoma (HCC) patients is partially unsatisfactory. Systemic therapy and TACE are widely used in BCLC-B stage HCC patients. This study aims to explore the efficacy of combining systemic therapy with transarterial-based therapy in unresectable BCLC-B stage HCC patients.
Methods
A total of 76 newly diagnosed HCC patients with BCLC-B stage were included in this retrospective cohort study. These patients were divided into two groups: TACE combined with atezolizumab and bevacizumab group (TACE-AT group, n=37) and TACE monotherapy group (TACE group, n= 39). Propensity score matching was used to account for potential confounding factors. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), liver function, and adverse events (AEs) were recorded and evaluated.
Results
After propensity score matching, 31 patients were assigned to each group.The TACE-AT group showed higher overall response rate [93.5%(29/31) vs. 48.4%(15/31), P<0.001] than the TACE group.Furthermore, the TACE-AT group showed longer median PFS (8.4 vs. 4.8 months; hazard ratio [HR], 0.239, P <0.001) than the TACE group. The TACE-AT group showed better OS than the TACE group (median OS not reached vs. 19.4 months, P <0.001). There was no significant difference in disease control rate between the two groups.The grade 3/4 adverse events rates were similar between the two groups (19.3% vs. 25.4%, P=0.082).
Conclusions
The combination of TACE, atezolizumab and bevacizumab provides clinical benefits for patients with intermediate HCC, has an acceptable safety profile, shows a trend towards improving liver function, and does not increase the occurrence of grade 3-4 AEs.
Legal entity responsible for the study
H. Cai.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
137P - Hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study
Presenter: Jianbing Wu
Session: Poster Display session
138P - Interim results of neoadjuvant TACE plus lenvatinib and tislelizumab in resectable HCC at CNLC stages IB and IIA with high-risk of recurrence: A prospective, single-arm, phase II trial
Presenter: Yuhua Zhang
Session: Poster Display session
139P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display session
140P - Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective, single-arm, phase II study
Presenter: Zhibo Zhang
Session: Poster Display session
141P - Efficacy and safety of tislelizumab(T) combined with gemcitabine and cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: A prospective, phase II study
Presenter: Ming Cao
Session: Poster Display session
Resources:
Abstract
143P - Strength of patient (pt) preference for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC: exploratory analyses from the IMscin002 study
Presenter: Margarita Majem Tarruella
Session: Poster Display session
144P - First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1
Presenter: Tamta Makharadze
Session: Poster Display session
145P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: An update of the phase II, prospective study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display session
Resources:
Abstract